Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
复制标题
DOI：
10.1182/blood.2021012152
复制
发表时间：
2021-07-29
期刊：
影响因子：
20.3
通讯作者：
Ortel TL
中科院分区：
文献类型：
--
作者：
Arepally GM;Ortel TL
在本期《血色聚焦》中，Aepally和Ortel讨论了关于Vitt的最新信息，并强调了关键的“已知”和相关的“未知”。他们还回顾了对腺病毒新冠肺炎疫苗这种罕见但重要的并发症的适当治疗。对抗新冠肺炎的疫苗的开发一直是一项了不起的医学成就。然而，这种全球免疫努力因一种罕见的疫苗相关结果而变得复杂，其特征是血小板减少和血栓形成，并与血小板激活抗血小板因子4抗体相关。在这一集中，我们将讨论最近被描述的疫苗诱导的免疫性血栓性血小板减少症(VITT)的并发症，该并发症发生在某些新冠肺炎疫苗的反应中。虽然关于这种临床情况的信息正在迅速演变，但我们将总结我们目前对VITT的理解。
In this timely Blood Spotlight, Arepally and Ortel discuss the latest information about VITT and highlight key “knowns” as well as pertinent “unknowns.” They also review appropriate treatments for this rare, but important complication of adenoviral COVID-19 vaccines. The development of vaccines to fight COVID-19 has been a remarkable medical achievement. However, this global immunization effort has been complicated by a rare vaccine-related outcome characterized by thrombocytopenia and thrombosis in association with platelet-activating anti–platelet factor 4 antibodies. In this Spotlight, we will discuss the recently described complication of vaccine-induced immune thrombotic thrombocytopenia (VITT) occurring in response to certain COVID-19 vaccines. Although information about this clinical condition is rapidly evolving, we will summarize our current understanding of VITT.